Below are all the abstracts related to ROS1 NSCLC listed in the scientific program for the 2019 IASLC World Conference on Lung Cancer in Barcelona, Spain September 7-10. While the times and locations of sessions may change, the numbers and names will not. ES14 – What First Line in Oncogene Addicted NSCLC 15:15 – 16:45 … Continue reading ROS1 abstracts at #WCLC19
On May 16, 2019, ROS1der co-founder Janet Freeman-Daily interviewed ROS1 expert D Ross Camidge, MD, PhD, Director of Thoracic Oncology and the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado in a Zoom Webinar. We discussed questions that have arisen among experienced patients in The ROS1ders regarding diagnosis, treatment, and research … Continue reading The ROS1ders Interview Dr. Ross Camidge (16-May-2019)
Yesterday the pan-Canadian Oncology Drug Review (pCODR) process gave a positive initial recommendation for first-line crizotinib for ROS1+ NSCLC based on clear phase 2 data & Real World Evidence. A randomized Phase 3 study was not required. This is an essential step towards getting crizotinib reimbursed for patients across Canada. This submission was led by … Continue reading pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC
One of the founders of the ROS1ders, Janet Freeman-Daily, shares her story and why she advocates for molecular testing, clinical trials, and the positive changes she’s seen. “Given that lung cancer patients often don’t have much tumor tissue, we should make the best use of it, and running an NGS test is the best chance … Continue reading Advocating for ROS1
I’m Janet Freeman-Daily, a cofounder of The ROS1ders. I’m writing this post in response to some of the comments we’ve seen recently in our private Facebook group “ROS1 Positive (ROS1+) Cancer.” Many of our members who have ROS1+ cancers take the targeted therapy crizotinib (Xalkori), a tyrosine kinase inhibitor (TKI). It was approved by the … Continue reading Thinking about a “drug vacation” from crizotinib? Read this first!
Lung Cancer Canada is collecting data to support approval of crizotinib for ROS1+ non-small cell lung cancer in their country. Their deadline for submission is rapidly approaching, and they need more data to strengthen their case. They would like ROS1+ patients who have taking crizotinib to share the following information (no names): Demographic data (e.g., … Continue reading ATTENTION ALL ROS1+ CANCER PATIENTS! Canadian ROS1 patients need our help ASAP!